This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna
®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that the company will report financial results for the three months ended June 30, 2013, before the opening of trading on Wednesday, August 14
th. The company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 8 A.M. Eastern Time on Wednesday, August 14
Conference Call and Webcast Details
To listen to the conference call, dial in approximately ten minutes before the scheduled 8 AM time to (253) 237-1170 or toll free at (877) 372-0867. Please reference conference ID #31008302 while dialing into the call.
A live webcast of the call can also be accessed via the webcast link on our website (
www.opexatherapeutics.com) or by going to the following URL:
There will be a brief Question & Answer session following management commentary. Shareholders and interested parties are highly encouraged to submit questions in advance by e-mail addressed to
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders. The Company’s leading therapy candidate, Tcelna
®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells isolated from the patient’s peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.
About Multiple Sclerosis (MS)
Multiple Sclerosis is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.